Showing results (451-460 of 976) with videos related to

Sort By:
Pageof 98
NPJ Breast Cancer|September 27, 2023
Predictive modelling of response to neoadjuvant therapy in HER2+ breast cancerNicola Cosgrove, Alex J Eustace, Peter O'Donovan, et al.
NPJ Breast Cancer|October 20, 2023
Adipose-enriched peri-tumoral stroma, in contrast to myofibroblast-enriched stroma, prognosticates poorer survival in breast cancersHannah Si Hui Lau, Veronique Kiak Mien Tan, Benita Kiat Tee Tan, et al.
NPJ Breast Cancer|September 8, 2023
Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancerAlessandra Fabi, Luisa Carbognin, Andrea Botticelli, et al.
NPJ Breast Cancer|February 25, 2026
Socioeconomic disparities in long-term heart failure risk of trastuzumab with or without anthracyclines in early-stage breast cancer: a SEER-Medicare database analysisKarissa Britten, Marla Lipsyc-Sharf, Eric H Yang, et al.
NPJ Breast Cancer|March 15, 2026
HIF-1-regulated TPM3 links hypoxia to motility and invasion beyond the hypoxic fraction in triple-negative breast cancerChumin Zhou, Jack T Crusher, Kate Friesen, et al.
NPJ Breast Cancer|March 15, 2026
Preclinical models of breast cancer metastasis: strengths, limitations, and clinical relevancePatrick Aouad, Karim Halabi, Berthe Hayar, et al.
NPJ Breast Cancer|March 5, 2026
RAD51-based homologous recombination deficiency is associated with treatment response and survival in early breast cancerAlba Llop-Guevara, Benedetta Pellegrino, Isabel Pimentel, et al.
NPJ Breast Cancer|February 27, 2026
The landscape of the intestinal microbiome among patients with newly diagnosed invasive breast cancer and ductal carcinoma in situ (DCIS)Sarah L Sammons, Thomas M Kuntz, Molly DiLullo, et al.
NPJ Breast Cancer|February 26, 2026
No evidence for genotype-treatment interactions with breast cancer endocrine therapy adverse effects in UK BiobankKinan Mokbel, Michael N Weedon, Victoria Moye, et al.
NPJ Breast Cancer|March 18, 2026
Peri-lymphatic cytokines (IRX-2) as immunologic induction preceding neoadjuvant chemo-immunotherapy in triple-negative breast cancerAlan Su, Erin C Hong, Nicole Moxon, et al.
Pageof 98